Updates are available Correction dated 2019-08-16
Click to view Correction: https://doi.org/10.1038/s41591-019-0572-6
-
Authors
Abdel-Gadir, Azza
Stephen-Victor, Emmanuel
Gerber, Georg K.
Noval Rivas, Magali https://orcid.org/0000-0001-5570-8928
Wang, Sen
Harb, Hani https://orcid.org/0000-0001-8218-2538
Wang, Leighanne
Li, Ning
Crestani, Elena
Spielman, Sara
Secor, William
Biehl, Heather
DiBenedetto, Nicholas
Dong, Xiaoxi https://orcid.org/0000-0003-3852-331X
Umetsu, Dale T.
Bry, Lynn
Rachid, Rima https://orcid.org/0000-0002-7485-8742
Chatila, Talal A. https://orcid.org/0000-0001-7439-2762
- License Information
-
More Information
Article History
Received: 2 August 2018
Accepted: 18 April 2019
First Online: 24 June 2019
Change Date: 16 August 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: L.B., G.K.G., T.A.C., R.R. and A.A.-G. are inventors on published US patent application No. 15/801,811, submitted by The Brigham and Women’s Hospital, Inc. and Children’s Medical Center Corporation, that covers methods and compositions for the prevention and treatment of food allergy using microbial treatments. T.A.C., R.R., A.A.-G. and E.S.-V. have pending patent applications related to the use of probiotics in enforcing oral tolerance in food allergy (Nos. 62/758, 161, and 62/823,866). L.B., G.K.G. and T.A.C. are founders of, and have equity in, Consortia Tx. R.R. has equity in Consortia Tx. A.A.-G. is currently an employee of, and owns shares in, Seed Health Inc. The rest of the authors declare no competing interests.
